Search

Displaying results 871 - 880 of 10000 in total
  1. Drug

    Asfotase alfa

    go.drugbank.com/drugs/DB09105
    ApprovedInvestigational

    Asfotase alfa was first approved by Pharmaceuticals and Medicals Devices Agency of Japan (PMDA) on July 3, 2015, then approved by the European Medicine Agency (EMA) on August 28, 2015, and was approved … Food and Drug Administration (FDA) on October 23, 2015. Asfotase Alfa is marketed under the brand name Strensiq® by Alexion Pharmaceuticals, Inc.

  2. Drug

    Riociguat

    go.drugbank.com/drugs/DB08931
    ApprovedInvestigational

    Riociguat is a soluble guanylate cyclase (sGC) agonist approved in the USA, Europe and several other regions for patients with group I PAH (pulmonary arterial hypertension) in WHO FC II or III; and for … the treatment of patients with inoperable CTEPH (chronic thromboembolic pulmonary hypertension), or persistent/recurrent PH (pulmonary hypertension) after pulmonary endarterectomy in WHO FC II or III.

    Synonyms: Methyl N-[4,6-Diamino-2-[1-[(2-fluorophenyl)methyl]-1H-pyrazolo[3,4-b]pyridin-3-yl]-5-pyrimidinyl]-N-methyl-carbaminate
  3. Drug

    Methyl salicylate

    go.drugbank.com/drugs/DB09543
    ApprovedInvestigationalVet approved

    It is used as a flavoring agent in chewing gums and mints in small concentrations and added as antiseptic in mouthwash solutions. … The compound was first extracted and isolated from plant species Gaultheria procumbens in 1843. It can be manufactured synthetically and it used as a fragrance, in foods, beverages, and liniments.

    Mixtures: EZ-Relief, Air Sinsinpas-EXCategories: Compounds used in a research, industrial, or household setting, Complex Mixtures
  4. Drug

    Cetirizine

    go.drugbank.com/drugs/DB00341
    ApprovedInvestigational

    Cetirizine, also commonly known as _Zyrtec_, is an orally active second-generation histamine H1 antagonist proven effective in the treatment of various allergic symptoms, such as sneezing, coughing, nasal … The prevalence of allergic rhinitis in the United States is about 15% according to physician diagnoses, and up to 30%, according to self-reported nasal symptoms.

    Mixtures: Cetirizine HCl and Pseudoephedrine HCl ER, Cetirizine HCl and Pseudoephedrine HCl ERProducts: H-E-B Allergy Relief, CETIRIZINA EG
  5. Drug

    Voxelotor

    go.drugbank.com/drugs/DB14975
    Approved

    [T734] Voxelotor was granted accelerated FDA approval on November 25 2019, as it is likely to be a promising treatment for the 100,000 individuals in the U.S. suffering from the disease, in addition … This is a genetically inherited condition most prevalent in the Middle East, Africa, and certain parts of India.

  6. Drug

    Cerliponase alfa

    go.drugbank.com/drugs/DB13173
    ApprovedInvestigational

    [L51339] It was also approved by the EMA on May 30, 2017 [L51324] and by Health Canada on December 19, 2018. … [A264354, A264369] As a recombinant human TPP1, cerliponase alfa is used as an enzyme replacement therapy to restore the levels of TPP1 in patients with CLN2.[L51339]

    Categories: Hydrolytic Lysosomal N-terminal Tripeptidyl Peptidase
  7. Drug

    Viloxazine

    go.drugbank.com/drugs/DB09185
    ApprovedInvestigationalWithdrawn

    [L41685] For decades, an immediate-release formulation of viloxazine has been used in Europe as an antidepressant. … In the US, viloxazine was assigned an orphan drug designation in 1984 under the brand name CATATROL: while this product was intended to treat cataplexy and narcolepsy, the drug was never approved for these

  8. Drug

    Glycine

    go.drugbank.com/drugs/DB00145
    ApprovedInvestigationalNutraceuticalVet approved

    It is found primarily in gelatin and silk fibroin and used therapeutically as a nutrient. It is also a fast inhibitory neurotransmitter.

    Mixtures: POLİNUTHREE EN-550 ELEKTROLİTLİ AMİNOASİT ÇÖZELTİSİ, GLUKOZ ÇÖZELTİSİ, VE LİPİD EMÜLSİYONU, 1000 ML, POLİNUTHREE EN-550 ELEKTROLİTLİ AMİNOASİT ÇÖZELTİSİ, GLUKOZ ÇÖZELTİSİ, VE LİPİD EMÜLSİYONU, 1500 ML
  9. Drug

    Avacopan

    go.drugbank.com/drugs/DB15011
    ApprovedInvestigational

    [L38919] On January 19, 2022, the European Commission approved avacopan for the treatment of adult patients with severe, active granulomatosis polyangiitis (GPA) or microscopic polyangiitis (MPA) - the … [A240249, A240254] Despite complex pathophysiology, studies over the past ~2 decades have identified a key role for the alternative complement pathway and, in particular, the interaction between the anaphylatoxin

  10. Drug

    Dextran

    go.drugbank.com/drugs/DB09255
    ApprovedInvestigationalVet approved

    Dextran 75 is a complex branched glucan with an average molecular weight 75000 Daltons. … When labelled with technetium Tc99m, dextran 75 is intravenously administered as an imaging agent to detect and diagnose conditions in the vascular compartment such as pericardial effusion or ventricular

    Mixtures: RHEOMACRODEX EN SOLUCIÓN GLUCOSADA, RHEOMACRODEX EN SOLUCIÓN SALINA ISOTÓNICACategories: Compounds used in a research, industrial, or household setting